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Abstract 
Skeletal muscle insulin resistance in obesity associates with mitochondrial dysfunction, but 
the causality of this association is controversial. This review evaluates mitochondrial models 
of nutrient-induced muscle insulin resistance. It transpires that all models predict that insulin 
resistance arises as a result of imbalanced cellular bioenergetics. The nature and precise 
origin of the proposed insulin-numbing molecules differ between models but all species only 
accumulate when metabolic fuel supply outweighs energy demand. This observation 
suggests that mitochondrial deficiency in muscle insulin resistance is not merely owing to 
intrinsic functional defects, but could instead be an adaptation to nutrient-induced changes in 
energy expenditure. Such adaptive effects are likely because muscle ATP supply is fully 
driven by energy demand. This market-economic control of myocellular bioenergetics offers 
a mechanism by which insulin-signalling deficiency can cause apparent mitochondrial 
dysfunction, as insulin resistance lowers skeletal muscle anabolism and thus dampens ATP 
demand and, consequently, oxidative ATP synthesis. 
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1. INTRODUCTION 
The concentration of blood glucose needs to be maintained within a relatively narrow range 
as hypoglycemia and hyperglycemia cause medical complications [1-3]. Despite fluctuating 
nutrient supply, healthy people achieve tight glycemic control through well-orchestrated 
biochemical interplay between organs. When circulating glucose rises, for example after a 
meal, pancreatic  cells increase glucose uptake and breakdown thus fueling mitochondrial 
respiration and boosting ATP synthesis through oxidative phosphorylation – the consequent 
glucose-induced rise in the cytoplasmic ATP/ADP ratio is a key signal that provokes  cells 
to secrete insulin [4]. In turn, the rise in circulating insulin instructs a range of different 
organs – including skeletal muscle, liver, white adipose tissue and the brain – to adjust their 
activity to the elevated nutrient supply and restore the glucose concentration to its original 
level. For instance, skeletal muscle takes up much glucose in response to insulin and, given 
its comparably large mass, is responsible for more than 70% of total body glucose disposal 
[5]. Insulin sensitivity of skeletal muscle is thus of critical importance for maintaining blood 
glucose homeostasis. 
Although human insulin sensitivity varies naturally [6-8], persistent insulin resistance reflects 
a pathological state that associates firmly with disease. Monogenic deficiencies are for 
example responsible for severe insulin resistance syndromes [9,10], whilst environmental 
cues account for the loss of insulin sensitivity that links to diseases like type 2 diabetes [11]. 
Insulin resistance is a key feature of the Metabolic Syndrome, a cluster of disorders that 
collectively increase the risk of developing type 2 diabetes and cardiovascular disease [12]. 
Obesity is also a hallmark of this syndrome and indeed appears to be the most significant 
environmental risk for the development of insulin resistance [11,13]. 
The mechanism by which obesity causes skeletal muscle insulin resistance is incompletely 
understood, but bioenergetic failure has been implicated, which is not surprising as acquired 
obesity reflects an imbalanced whole body energy metabolism. However, the causal relation 
between mitochondrial dysfunction and insulin resistance is disputed fiercely. Irrespective of 
causality, the relative importance of mitochondrial functions that associate with loss of insulin 
sensitivity remains unclear. This review evaluates mitochondrial models of nutrient-induced 
insulin resistance of skeletal muscle, which all predict that pathology emerges when nutrient 
supply outweighs energy demand. Technical issues that may account for discrepancies 
between studies are described and it is emphasised that possible mitochondrial deficiency is 
best evaluated in context of cellular bioenergetic control. 
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2. INSULIN SENSITIVITY 
2.1 Signalling 
Insulin-sensitive cells express receptors that phosphorylate insulin receptor substrates (IRS1 
in skeletal muscle) when activated by insulin triggering 2 major protein kinase cascades, the 
phosphatidylinositol 3-kinase (PI3K) – protein kinase B (AKT) and the Ras-mitogen-activated 
protein kinase (MAPK) pathway [14] (Fig. 1). The insulin receptor (IR) and IRS isoforms are 
a ‗critical node‘ in a complicated insulin signalling network that permits direct interaction with 
several other pathways, for example initiated by insulin growth factor-1 and cytokines [15]. 
Both IR and IRS1 are activated by tyrosine phosphorylation, and inhibited by protein tyrosine 
phosphatases (PTPs) and serine phosphorylation [15]. When activated in skeletal muscle, 
IRS1 recruits and activates PI3K that, in turn, allows activation of AKT2 [15]. As reviewed by 
others [16-18], the PI3K-AKT pathway is a mechanism that induces recruitment of glucose 
transporter protein (GLUT-4) to the plasma membrane and thus mediates the considerable 
insulin-stimulated muscle glucose uptake. The same pathway inactivates glycogen synthase 
kinase-3 [15], which promotes a net decrease of the extent to which glycogen synthase 
(amongst other enzymes) is phosphorylated, and thus accounts for the insulin stimulation of 
glycogenesis [19]. Additional muscle processes promoted by insulin include mitochondrial 
biogenesis [20], mitochondrial protein synthesis [21] as well as cell growth and differentiation 
[22]. The PI3K-AKT pathway mediates the additional anabolic effects of insulin through 
stimulation of the mammalian target of rapamycin [23], whilst the MAPK pathway cooperates 
to transmit the message of insulin to increase skeletal muscle growth and differentiation [14]. 
 
Figure 1 – Skeletal muscle insulin signalling. Insulin activation of its receptor (IR) and receptor substrate 
(IRS1) triggers both the PI3K–AKT and MAPK pathways that transmit insulin‘s message for skeletal muscle to 
engage with a series of anabolic processes. The main result is increased glucose uptake. GSK3, glycogen 
synthase kinase-3; mTOR, mammalian target of rapamycin. 
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2.2 Bioenergetics 
Glycogen storage is a well understood and corroborated anabolic fate of the glucose that is 
taken up by muscle in response to insulin [24]. Alternatively, the muscle-disposed glucose 
may have a catabolic destiny conserving energy as ATP [25-27] (Fig. 2). Insulin stimulation 
of muscle ATP synthesis has been attributed to increased mitochondrial oxidative capacity 
[25] as it coincides with enhanced mitochondrial protein synthesis [21,25] and with increased 
mRNA levels and activities of mitochondrial enzymes involved with substrate catabolism 
[25]. Consistently, insulin stimulates glucose oxidation [28], mitochondrial biogenesis [20] as 
well as coupling efficiency of oxidative phosphorylation [29]. It is important to note, however, 
that muscle bioenergetics are almost fully controlled by energy demand (cf. section 5), such 
that ATP supply adapts rapidly to any change in ATP turnover [30]. Therefore, insulin effects 
on glucose oxidation may well be the indirect consequence of anabolic changes (Fig. 2) as 
the muscle processes that are stimulated by insulin all rely on endergonic mechanisms. 
Glucose uptake involves targeted exocytosis of intracellular compartments that sequester 
GLUT-4 protein [17] and thus relies on GTP-driven trafficking pathways [31]. Glycogenesis 
consumes both ATP and UTP, which is necessary to activate glucose molecules before 
glycogen synthase can add them to the extending glucan chains [32]. Protein synthesis and 
DNA synthesis are needed for promoting cell growth (including mitochondrial biogenesis) 
and differentiation, and represent major ATP consuming processes [33,34]. 
 
Figure 2 – Insulin effects on cellular bioenergetics. Glucose disposed in response to insulin can be broken 
down to produce ATP. This catabolic fate is supported by insulin stimulation of mitochondrial ATP synthesis, 
which may also indirectly result from increased energy demand of anabolic processes stimulated by insulin. 
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3. INSULIN RESISTANCE 
Obesity is characterized by elevated levels of circulating non-esterified fatty acids (NEFAs) 
and cytokines [35,36]. This excess of nutrients and inflammatory molecules is believed to 
link obesity causally with muscle insulin resistance [37], but exact mechanisms remain to be 
established. Cytokines activate inflammation- and stress-related signalling pathways that 
directly intersect with the insulin signalling network [15]. Cytokines may also influence insulin 
signalling by triggering unfolded protein response pathways under conditions that cause 
endoplasmic reticulum (ER) stress [38-40]. The role of ER stress in the pathology of insulin 
resistance in muscle, however, is currently unclear [38]. When faced with a chronic NEFA 
surplus, skeletal muscle cells produce many lipid species that link with decreased insulin 
sensitivity [41-49]. Species include triacylglycerol (TAG), diacylglycerol (DAG), ceramide and 
derived gangliosides, and acylcarnitines, which could in principle be considered maladaptive 
signals that arise from disordered lipid metabolism [50,51] when nutrient supply outweighs 
energy demand. Bioenergetic failure indeed features in most suggested explanations for the 
emergence of harmful lipids, but models differ on the precise involvement of mitochondrial 
activity (cf. section 4). Moreover, imbalanced energy metabolism also disturbs cellular redox 
biology [52,53], which is reflected by generation of undesirable reactive oxygen species ([54] 
– ROS) that dampen insulin sensitivity. Reactive nitrogen species may also play a role [55]. 
3.1 Lipids 
Strong association between intramyocellular TAG and skeletal muscle insulin sensitivity was 
established towards the end of last century [56-58] and has since been firmly established in 
rodent models of metabolic disease [59,60]  and in obese and diabetic humans [61-63]. 
However, the occurrence of intramuscular TAG is not deleterious per se, as is evident from 
the so-called athlete‘s paradox that embodies the counterintuitive observation that muscle 
lipid content of highly trained people correlates positively with their insulin sensitivity and 
oxidative capacity [64]. Indeed, endurance-trained athletes may accumulate as much, if not 
more, ectopic TAG than insulin-resistant type 2 diabetes patients [65]. TAG-containing lipid 
droplets are highly dynamic entities [66], however, and their high turnover is now generally 
held responsible for the production of deleterious lipid species that cause insulin resistance. 
In this respect, evidence has accrued for the notion that DAG and ceramide link to muscle 
insulin resistance [44,46]  (Fig. 3). 
DAG accumulates in isolated NEFA-exposed myotubes [67] and its level is increased in 
skeletal muscle of metabolically compromised rodent models [60,68,69] and of humans 
exhibiting lipid-induced muscle insulin resistance [70,71]. The mechanism by which DAG 
lowers insulin sensitivity of mice [72] and human [70,71] involves a novel protein kinase C 
isoform (PKC), whose activation dampens insulin signalling via serine phosphorylation of 
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IRS1 ([73,74] – Fig. 3). Together, these studies provide compelling evidence to suggest that 
DAG is a causative mediator of obesity-related muscle insulin resistance. However, the link 
is not universal since the exquisitely insulin-sensitive athletes mentioned above exhibit 
higher intramuscular DAG levels than their sedentary equivalents, either of normal weight or 
obese [75]. Related, insulin resistance in obese people does not always coincide with higher 
DAG levels [76] and, reciprocally, high myocellular DAG does not necessarily imply loss of 
insulin sensitivity, as has recently been demonstrated in mice [77]. Differences in subcellular 
localization and composition/saturation of DAG species possibly explain the discrepancies 
between studies [78]. 
 
Figure 3 – Disturbance of skeletal muscle insulin signalling by lipids. Diacylglycerol (DAG) and ceramide 
activate atypical protein kinase C (PKC) isoforms that inhibit the insulin receptor substrate (IRS1) and protein 
kinase B (AKT2), respectively. Ceramide also achieves AKT2 inhibition through activation of protein phosphatase 
2A (PP2A). GM3 is a ceramide-derived ganglioside that inhibits the insulin receptor (IR). 
 
Skeletal muscle ceramide levels are elevated in insulin-resistant rodent models [79-82], 
obese humans [75,76,83,84], and in palmitate-exposed C2C12 myocytes [85]. Ceramide 
dampens insulin signalling by inhibiting AKT2 activity [81,85-91] (Fig. 3) by blocking its 
translocation to the plasma membrane via activation of atypical PKC isoform zeta (PKC) 
[89], and by promoting its dephosphorylation via protein phosphatase 2A (PP2A) activation 
[88,90]. In spite of this mechanistic support, the link between ceramide and muscle insulin 
resistance is not absolute as human skeletal muscle rendered insulin-insensitive by acute 
lipid infusion does not exhibit increased ceramide levels [71], whilst a positive link between 
ceramide and insulin sensitivity has indeed also been reported [92]. 
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Gangliosides are ceramide-derived glycosphingolipids that can influence receptor-mediated 
signal transduction [49]. Inhibition of glycosphingolipid synthesis [93] or genetic ablation of 
ganglioside GM3 [94] for example enhances murine insulin sensitivity, a phenotype that links 
with increased tyrosine-phosphorylation of the insulin receptor ([94] – Fig. 3). Consistently, 
skeletal muscle insulin-resistance in obese rats links to low abundance of NEU3 sialidase, 
an enzyme responsible for GM3 degradation, and such degradation is repressed when L6 
myocytes are exposed to fatty acids [95]. In contrast, transgenic mice overexpressing NEU3 
sialidase exhibit lowered insulin sensitivity [96]. 
Increased but incomplete mitochondrial beta oxidation in various insulin-resistant skeletal 
muscle models coincides with a rise in acylcarnitines [97]. Such species indeed accumulate 
in human muscle [98] and plasma  [99,100] when subjects are fed a high-fat diet, but signs 
of incomplete NEFA oxidation are not always detected [100]. It is possible that acylcarnitines 
are merely guilty by association and that the real culprits are the acyl-CoA esters from which 
they derive. In this respect, it is relevant that carnitine insufficiency associates with insulin 
resistance [101] and that carnitine supplementation improves insulin sensitivity [102,103]. 
Irrespective of their carrier, it is currently unclear how fatty acyls may provoke insulin 
resistance [47,51], but it should be noted that insulin resistance may emerge independently 
of changes in canonical insulin signalling [104] and that sirtuin-mediated protein deacylation 
is a mechanism with impact on the metabolic syndrome [105-107] that could conceivably 
afford fatty acyl moieties control over insulin resistance [108].3.2 Reactive oxygen species 
The relation between ROS and insulin sensitivity is a delicate one, as skeletal muscle does 
not respond optimally to insulin without ROS engagement [109], but becomes resistant to it 
when ROS levels are persistently high [53,54]. This duality underscores the importance of 
ROS in cell signalling [110] and highlights the need for tight regulation of their production 
and turnover, as chronic ROS surplus causes oxidative stress [111]. 
Mitochondrial hydrogen peroxide (H2O2) release in permeabilised skeletal muscle fibers from 
rats and humans is increased by a high-fat diet that renders these muscles insulin resistant 
[112]. Diet-induced loss of insulin sensitivity is prevented in rats when their antioxidant 
capacity is increased either pharmacologically with mitochondria-targeted antioxidants or 
genetically through the overexpression of mitochondrial catalase [112]. Similarly, increased 
antioxidant capacity in transgenic mice that globally overexpress peroxiredoxin 3, decreases 
H2O2 release from isolated skeletal muscle mitochondria, an effect that links with improved 
systemic glucose tolerance of these mice [113]. Mopping up mitochondrial superoxide with 
superoxide dismutase mimetics largely prevents development of palmitate-induced insulin 
resistance in cultured L6 myotubes, whilst antimycin A-stimulated mitochondrial superoxide 
lowers insulin sensitivity of such cells [114]. Consistently, mice overexpressing mitochondrial 
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superoxide dismutase [114] or catalase [115], are partly protected against insulin resistance 
resulting from a high-fat diet and old age, respectively. Although some evidence is indirect 
(cf. section 5.2.1), the observations suggest ROS cause insulin resistance, a mechanism 
first demonstrated in adipocytes and, systemically, in mice [116]. In addition to [112], a few 
more associations between obesity and markers of oxidative stress have been reported in 
human [117,118], and it is worth notice that lipid peroxide levels are increased in skeletal 
muscle of obese subjects [119]. 
 
Figure 4 – Disturbance of skeletal muscle insulin signalling in obesity by reactive oxygen species. H2O2 is 
able to both promote and attenuate insulin-provoked glucose uptake (green and red lines, respectively). Inhibition 
of phosphatases such as the phosphatase and tension homologue (PTEN) and protein tyrosine phosphatase 1B 
(PTP1B) stimulates insulin signalling, whereas inhibition of PP2A dampens signalling secondary to activation of 
stress-sensitive kinases including c-Jun N-terminal Kinase (JNK), extracellular signal regulated kinase (ERK) and 
inhibitory- kinase  (IKK). See text for further detail. 
 
ROS is an umbrella term that covers a mixed bunch of species with different chemical and 
biological properties. In this respect, H2O2 is the most likely ROS to act as a second 
messenger, largely owing to its ability to oxidise thiols [110] and thus to regulate the redox 
proteome [120]. Indeed, through oxidation of cysteine sulphydryl groups, H2O2 inhibits global 
phosphatase (PP2A) activity in skeletal muscle [121], which causes activation of a series of 
stress-sensitive kinases (including JNK, ERK and IKK) that in turn inhibit IRS1 via serine 
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phosphorylation ([122] – Fig. 4). By similar modulation of ‗cysteine switches‘, H2O2 inhibits 
protein tyrosine phosphatases such as PTP1B [123] and PTEN [53], which prevents 
deactivation of IRS1 and PI3K, respectively (Fig. 4), and is held responsible for physiological 
H2O2 stimulation of insulin signalling. 
3.3 Reactive nitrogen species 
Obesity and type 2 diabetes are characterized by decreased NO bioavailability in animals 
[124,125] and human [126,127]. NO deficiency is owing to decreased nitric oxide synthase 
(NOS) activity, and to reactivity with ROS that may effectively act as NO scavengers [55]. 
Endothelial NOS3 exhibits insulin-sensitizing effects promoting insulin and glucose delivery 
to muscle [128] and stimulating muscle fat oxidation [129]. Interestingly, vascular endothelial 
NO limitation may be overcome by dietary nitrate supplementation [130,131]. Dietary nitrate 
reverses metabolic defects of NOS3-deficient mice [130], and benefits glucose homeostasis 
in rodents [132,133]. Moreover, nitrite and NO stimulate insulin signalling in L6 muscle cells 
by increasing GLUT4 recruitment [132]. Mechanisms by which dietary nitrate affects skeletal 
muscle bioenergetics are reviewed elsewhere [134]. Muscle NO appears less beneficial than 
vascular NO [55] as muscle-inducible NOS2 promotes insulin resistance in mice [135] via S-
nitrosation of the insulin receptor (IR), IRS1 and AKT [136,137]. 
4. MITOCHONDRIAL MODELS OF INSULIN RESISTANCE 
Acquired obesity results from imbalanced systemic energy metabolism and it thus comes as 
no surprise that mitochondria are implicated heavily in the skeletal muscle insulin resistance 
that arises from chronic over-nutrition. Lipid intermediates and ROS have been suggested to 
accumulate in muscle as a result of nutrient mismanagement. Breakdown of major dietary 
nutrients converges in mitochondria where turnover of common carbon compounds 
produces reducing power that fuels oxidative phosphorylation (Fig. 5). When energy demand 
is low, mitochondrial carbon does not fuel ATP synthesis, but instead provides building 
blocks for anabolic processes such as lipid biosynthesis. Mitochondria are thus key to a well-
balanced nutrient metabolism and are likely players in the emergence of myocellular lipids 
and ROS in obesity. The following models of muscle insulin resistance are based on this 
premise. 
4.1 Oxidative capacity 
Work by Shulman and colleagues challenged the ‗Randle paradigm‘ [138,139] that NEFAs 
lower muscle insulin sensitivity by metabolic inhibition of glucose catabolism (cf. section 4.3). 
Spectroscopy-based measurements revealed that muscle glucose disposal in type 2 diabetic 
patients is limited by glucose uptake, an observation that led to the hypothesis that insulin-
stimulated GLUT4 recruitment is inhibited by lipid signalling molecules such as DAG and 
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ceramide [140] (Fig. 3). The oxidative capacity model of muscle insulin resistance predicts 
that ‗mitochondrial insufficiency‘ is responsible for the accumulation of these lipid anabolites, 
because it precludes  oxidation of the excess NEFAs that skeletal muscle faces in obesity 
[141,142] (Fig. 5). Originally based on links between human insulin resistance and 
decreased mitochondrial enzyme activity, fatty acid oxidation [143-146] and mitochondrial 
size [147], the prediction was corroborated by studies suggesting that rates of mitochondrial 
ATP synthesis and substrate oxidation – measured by molecular resonance spectroscopy 
(MRS, cf. section 5.2.1) – are comparably low in elderly individuals with insulin-resistance 
[148], in lean, young, but insulin-resistant offspring of type 2 diabetic parents [26,149,150], 
and in non-obese patients with well-controlled type 2 diabetes [151]. Low mitochondrial 
respiration was also found in type 2 diabetic patients when measured ex vivo [152,153]. The 
oxidative capacity prediction is further supported by molecular studies showing that PGC-1-
regulated oxidative phosphorylation genes are downregulated, in a coordinated manner, in 
human muscle of diabetic and insulin-resistant subjects [154,155] and in muscle of fat-fed 
individuals [156]. Despite much additional experimental evidence (cf. [44,48]), the oxidative 
capacity model is not supported universally. For example, human capacity for fat oxidation is 
not always increased in obese, insulin-resistant and type 2 diabetic subjects, as many 
studies have revealed opposite associations [157-165]. Consistently, rodent studies have 
revealed that intermittent increase of plasma fatty acids causes muscle insulin resistance in 
rats and stimulates mitochondrial biogenesis [166]. Furthermore, high-fat diet increases the 
mitochondrial  oxidation capacity of insulin-resistant mice [167] and rats [168]. Any decline 
in muscle oxidative capacity does not tend to manifest itself before several months of high-
fat feeding [169]. Recent studies into the relation between oxidative capacity and nutrient-
induced muscle insulin resistance continue to yield discrepant results [170-173]. 
4.2 Lipid overload and redox biology 
Muoio and colleagues first formulated the ‗lipid overload‘ model having shown that obesity-
related muscle insulin resistance associates firmly with intramuscular accumulation of fatty-
acylcarnitine species [97,174]. Although it is unclear whether or not acylcarnitines provoke 
insulin resistance per se (cf. section 3.1), these species are generated via acyltransferase-
catalysed conversion of equivalent fatty-acyl-coenzyme-A (CoA) esters, which are perhaps 
the true culprits, that build up during incomplete NEFA breakdown (Fig. 5). The model 
predicts that incomplete breakdown occurs when mitochondrial lipid supply increases the 
rate of  oxidation rate more than the tricarboxylic acid (TCA) cycle and the mitochondrial 
electron transfer chain can handle or, more generally, when total nutrient supply outweighs 
energy demand [45]. In support for the suggested mismatch in obesity between 
mitochondrial  oxidation on the one hand and TCA cycle turnover and mitochondrial 
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respiratory chain activity on the other, studies are cited [45] that show that  oxidation rate 
increases during early-stage nutrient-induced insulin resistance without change in 
mitochondrial respiratory capacity [168,175]. Further circumstantial support for the lipid 
overload model comes from links between acylcarnitine accumulation and insulin resistance 
in obese and type 2 diabetic human subjects [99,100,176-178] and in primary human 
skeletal muscle cells [179,180]. 
Chronic imbalance between the rate of  oxidation and the capacities of the TCA cycle and 
respiratory chain has also been suggested to increase mitochondrial ROS formation under 
conditions where fuel supply exceeds energy expenditure [53] (Fig. 5), which provides a 
mechanistic model as to how the H2O2 arises that dampens insulin signalling in obesity 
(section 3.2). This ‗redox biology‘ model of muscle insulin resistance [53] is conceptually 
similar to the ‗lipid overload‘ model, and acylcarnitines and H2O2 may well accumulate 
concomitantly owing to the same bioenergetic imbalance. Importantly, these models both 
predict that increased  oxidation of NEFAs attenuates insulin sensitivity, which sets them 
apart from the ‗oxidative capacity‘ model where insulin sensitivity is expected to improve as 
result of increased  oxidation [181]. It should be emphasised that effects on insulin 
sensitivity in this context will depend on the way in which increased lipid oxidation comes 
about. ‗Pushing‘ lipid catabolism via pharmacological or genetic stimulation of mitochondrial 
 oxidation will not prevent the accumulation of insulin-desensitising lipid intermediates 
(section 3.1) if insufficient demand for ATP precludes oxidation of the liberated reducing 
power. On the other hand, if lipid catabolism is ‗pulled‘ by stimulating energy expenditure, 
then increased  oxidation will not have any pathological ramification. In other words, if  
oxidation rate were amplified by increased ATP demand, for example secondary to physical 
exercise [182] or perhaps owing to decreased coupling efficiency of oxidative 
phosphorylation [183,184], then it is unlikely that DAG, ceramide, acylcarnitines or ROS 
would accumulate. Insulin-numbing species implicated by the ‗oxidative capacity‘, ‗lipid 
overload‘ and the ‗redox biology‘ models all only arise when cellular bioenergetic balance is 
disturbed (Fig. 5). It is thus possible that they contribute to insulin resistance in a concerted 
fashion. 
The balance between nutrient supply and energy demand determines whetherlipid oxidation 
associates with high or low ROS generation [53], which highlights that there is no unique 
relation between mitochondrial respiratory rate and ROS production [185]. Such a relation is 
frequently implied in redox biology literature where electron leak from the respiratory chain, 
which causes superoxide and H2O2 formation by incomplete reduction of oxygen, is often 
unhelpfully quantified as proportion of the total electron transfer rate through the chain. The 
driving force of ROS production is the reduction potential of the site that reduces oxygen 
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incompletely [186], not the mitochondrial respiratory rate. Depending on how mitochondrial 
oxygen consumption is stimulated, ROS production may increase or decrease [185]. The 
redox biology model assigns a role for mitochondrial H2O2 as both beneficial and deleterious 
effector of insulin signalling under physiological and obese conditions, respectively (Fig. 4), 
and it is argued that the phenotype depends on the strength and persistence of the H2O2 
signal [53]. It is equally conceivable that ‗good‘ and ‗bad‘ ROS are produced at different 
subcellular locations [54] or that the insulin signalling benefits are mediated by the ‗non-
radical‘ H2O2 [111], whilst insulin resistance emerges from ‗radical‘ oxidative stress (cf. 
section 5.2.2). 
 
Figure 5 – Mitochondrial models of skeletal muscle insulin resistance. Glucose (dark-blue arrows) is broken 
down glycolytically to pyruvate in the cytoplasm, which is oxidised to acetyl-coenzyme A (CoA) by the pyruvate 
dehydrogenase complex (PDC) after being imported to mitochondria. Non-esterified fatty acids (NEFAs – green 
arrows) are activated to fatty-acyl-CoA esters in the cytoplasm. Acyl groups can be exchanged between CoA and 
carnitine carriers by various acyltransferases (dotted lines – CrAT = carnitine acyltransferase). Acylcarnitines are 
transportable across mitochondrial membranes. Mitochondrial acyl-CoA esters are broken down to acetyl-CoA 
via  oxidation, a process that also yields reducing equivalents that can be oxidised by the mitochondrial electron 
transfer chain. Turnover of acetyl-CoA (dark-grey arrows) via the tricarboxylic acid (TCA) cycle also generates 
such reducing power. The energy that is liberated from electron transfer is conserved as ATP via oxidative 
phosphorylation (OXPHOS). Glucose and NEFAs are only fully oxidised in this manner when muscle cells need 
energy. When nutrient supply outweighs energy expenditure, the system backs up (thick red lines): a relatively 
low ATP demand will increase the ATP/ADP ratio, reduce components of the electron transfer chain, boost the 
mitochondrial NADH/NAD
+
 ratio, inhibit mitochondrial respiration, the TCA cycle and  oxidation, and provoke 
accumulation of acetyl-CoA and citrate, metabolites that inhibit PDC and phosphofructokinase, respectively. This 
reduced mitochondrial state promotes formation of molecules (DAG = diacylglycerol, ROS = reactive oxygen 
species) that act in various mitochondrial models of muscle insulin resistance: 1 = oxidative capacity (orange), 2 
= lipid overload (blue), 3 = redox biology (purple), 4 = metabolic inflexibility (pink). See text for further detail. 
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4.3 Metabolic inflexibility 
Metabolic flexibility can be defined as the capacity of human skeletal muscle to switch from 
lipid uptake and oxidation in a fasted state to glucose uptake, oxidation and storage in a fed 
state when insulin levels are increased [145]. Such switching between metabolic fuels was 
first described by Randle and colleagues who discovered that skeletal muscle cells suppress 
glucose oxidation when supplied with NEFAs and facilitate fat oxidation instead [138]. This 
Randle ‗cycle‘ [138,139] is achieved via acute metabolic regulation: increased mitochondrial 
 oxidation leads to accumulation of acetyl-CoA and citrate that lower glucose breakdown by 
respectively inhibiting the pyruvate dehydrogenase complex (PDC) and phosphofructokinase 
(Fig. 5). The consequent buildup of glucose-6-phosphate is accountable for inhibition of 
hexokinase, which, in turn, is suggested to limit glucose uptake [138,139].  Realizing that 
diabetes is characterized by increased circulating NEFA levels and decreased respiratory 
exchange ratios, it was proposed that the Randle cycle operates under conditions of nutrient 
excess and causes loss of muscle insulin sensitivity [187,188]. Interest in this metabolic 
dysregulation of insulin sensitivity faded a little when it was found that attenuated glucose 
uptake in obesity is caused by compromised GLUT4 recruitment instead of limited glucose 
phosphorylation [140]. Nonetheless, research on involvement of metabolic flexibility in the 
development of muscle insulin resistance has regained some momentum over recent years 
[108,189-191]. Muscle of obese subjects is characterized by a lack of metabolic flexibility, 
i.e., it does not exhibit the expected sharp shift from lipid to glucose oxidation upon transition 
from a fasted to an insulin-stimulated state [145]. The apparent inflexibility is largely owing to 
the already comparably high reliance of obese individuals on glucose oxidation in the fasting 
state [143] and lack of further increased glucose oxidation during insulin infusion may not be 
surprising given the existing insulin resistance. However, the absolute rate of lipid oxidation 
in obese muscle does not change between fasting and insulin-stimulated conditions, which 
forms the basis for the ‗metabolic inflexibility‘ model of muscle insulin resistance [145].  
Work by Muoio and colleagues [192] has provided new insight in the possible mechanism by 
which metabolic flexibility is lost in obesity, and has indeed revealed a novel mitochondrial 
player in the regulation of fuel selection. Carnitine acetyltransferase (CrAT) is located in the 
mitochondrial matrix where it converts acetyl-CoA and other short-chain fatty-acyl-CoAs to 
their equivalent, membrane-permeant carnityl esters. Acetyl-CoA export from mitochondria 
may alleviate PDC inhibition under conditions of high lipid availability, and emerging 
evidence indeed implicates CrAT deficiency in the development of muscle insulin resistance 
via a Randle-cycle-like mechanism (Fig. 5). For instance, muscle-specific CrAT knockout 
mice exhibit relatively high myocellular acetyl-CoA levels and low PDC activity, and have a 
diminished metabolic flexibility [192]. Dietary carnitine supplementation in human correlates 
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positively with circulating acetylcarnitine levels, glucose tolerance, and metabolic flexibility 
[192,193]. Moreover, skeletal muscle CrAT activity associates with insulin sensitivity in 
human and rodent models [194,195] and is inhibited in vitro by palmitoyl-CoA [195]. Under 
physiological conditions, acetylcarnitine may well serve as a carbon sink that facilitates 
continued glucose breakdown in the insulin-stimulated state when energy demand is 
relatively low. When such demand increases, the buffered acetyl can be readily mobilized 
again. In this model, supra-physiological nutrient supply would cause CrAT deficiency and 
thus disturb the acetyl buffering system. Although quantification of (reversible) acetyl transfer 
between CoA and carnitine under physiological and pathological conditions will be 
necessary to test the model directly, it is of interest that mice depleted from skeletal muscle 
CrAT exhibit decreased exercise tolerance and that effective acetyl buffering is necessary 
for optimal human exercise performance [196]. The CrAT-enabled safe carbon sink would 
stop the TCA cycle and mitochondrial respiratory chain from being overloaded with glucose-
derived acetyl-CoA when energy demand is low, and would thus prevent the accumulation of 
insulin-numbing molecules under such conditions (Fig. 5). The metabolic inflexibility model 
thus appears very similar indeed to the mitochondrial models of muscle insulin resistance 
discussed in sections 4.1 and 4.2. In this respect, the metabolic gridlock that has been 
suggested to emerge from ‗mitochondrial indecision‘ [108] will manifest itself whether or not 
fuel selection is regulated adequately. In other words, it seems unlikely that the TCA cycle 
should care about the origin of its acetyl-CoA (although compartmentalisation of 
mitochondrial acetyl-CoA is formally possible), and that oxidative phosphorylation should 
distinguish between the sources of its reducing equivalents. As long as there is energy 
demand, the system will make ATP irrespectively of the nutrients that fuel it, and equally 
indiscriminately, the system will back up when fuel supply outweighs ATP demand (Fig. 5). 
Several observations are relevant in this context. (i) Branched-chain amino acids may 
interact with NEFAs in the development of skeletal muscle insulin resistance [197] and their 
catabolism may contribute to the ‗metabolic gridlock‘ proposed to account for metabolic 
inflexibility [108]. This combined nutritional effect is consistent with the idea that imbalance 
of fuel availability and energy demand in obesity lowers insulin sensitivity irrespective of the 
nature of the nutrients that are in excessive supply. (ii) Genetic activation [198] and indirect 
metabolic inhibition [192] of PDC both associate with skeletal muscle insulin resistance. In 
both cases insulin resistance is likely owing to acetyl-CoA, which accumulates as result of 
direct PDC activation or CrAT ablation respectively. In other words, the reason for acetyl-
CoA accumulation is not important for its pathological consequences. (iii) Glycolytic inhibition 
of glucose breakdown does not necessarily exacerbate nutrient-induced insulin resistance 
[192], but may in fact ameliorate it [199], an apparent discrepancy that is explained by 
differences in total mitochondrial carbon accumulation between studies. (iv) AMP-activated 
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protein kinase overrules Randle cycle mechanisms for selecting fuels [200] (cf. section 6.1). 
Unregulated fuel selection thus appears not an issue when energy demand is relatively high. 
5. THE MITOCHONDRIAL CAUSALITY ISSUE 
5.1 Conflicting evidence 
Causality of the association between mitochondrial dysfunction and skeletal muscle insulin 
resistance is a controversial issue. The evidence in favour and against causal involvement of 
mitochondrial deficiency in disease development is split about equally, and ‗pro‘ and ‗contra‘ 
arguments are summarized in [201] and [202], respectively. Evidence in favour for a causal 
relation was provided in section 4. The counterargument is partly based on the assertion that 
obese muscle should have sufficient mitochondrial respiratory reserve to deal with excessive 
nutrient supply. This legitimate assertion is based on many studies showing that fat oxidation 
capacity is relatively high in obese, insulin-resistant and type 2 diabetic humans (cited in 
section 4.1), and is supported by the notion that type 2 diabetic patients increase their 
substrate oxidation rate some 40-fold in response to exercise [202]. However, ‗reserve 
oxidative capacity‘ will be of little use if cellular energy demand is low (cf. section 6.2). In 
addition to the rodent studies already cited [167,168], work on mouse models of 
mitochondrial dysfunction [203-205] is frequently used to argue against causal involvement 
of mitochondria in insulin resistance. Such models were generated by global genetic ablation 
of, respectively, the mitochondrial transcription factor Tfam [203], the mitochondrial 
apoptosis-inducing factor AIF [204] and the transcriptional coactivators PGC-1 and PGC-1 
[205]. Interestingly, impaired mitochondrial activity is not linked with loss of insulin sensitivity, 
but these ‗sledgehammer‘ approaches are somewhat confounded by likely non-
mitochondrial effects, direct and adaptive, of the genetic knockout. For instance, genetic 
disruption of mitochondrial energy conservation renders the animal models fully dependent 
on anaerobic glucose metabolism for ATP production, which is not the ideal background 
against which to evaluate metabolic interactions between fuels [201]. Skeletal-muscle-
specific knockout of carnitine palmitoyltransferase 1 more specifically prevents mitochondrial 
 oxidation of NEFAs [206]. Interestingly, muscle lipids accumulate in this mouse model 
without negative effect on insulin sensitivity [206]. Most compellingly, humans with inborn 
insulin signalling deficiency exhibit a decreased rate of phosphocreatine (PCr) recovery 
following exercise [207], which demonstrates that defects in muscle ATP synthesis follow, 
not precede, insulin resistance. Congenital lipodystrophy represents another inborn insulin 
resistance state and is also associated with a lowered PCr recovery rate [208]. The relation 
between mitochondrial function and skeletal muscle insulin sensitivity is evidently not a 
straightforward one, as is indeed suggested by the effect of short intensive exercise (cf. 
section 6) on muscle metabolism of healthy control individuals and offspring of mothers with 
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diabetes: whilst ATP synthesis in isolated muscle mitochondria is increased by exercise in 
both groups, insulin sensitivity is only improved in the controls [209].  
5.2 Measuring mitochondrial function 
It should be evident that the mitochondrial causality issue remains far from being settled. 
Some factors that complicate the issue have a technical nature and include evolving opinion 
on how best to measure cellular insulin sensitivity (generally, signalling activity appears most 
reliably quantified by measuring functional endpoints [104]) and heterogeneity of insulin 
resistance models. Indeed, discrepancies between studies may arise from variation in the 
extent to which insulin resistance has progressed in the different models. For instance, 
mitochondrial capacity increases early during development of rat muscle insulin resistance, 
but only transiently, as capacity returns to the initial level when obesity and insulin resistance 
progress [210]. Similarly, the muscle mitochondrial oxidative capacity declines in mice put on 
a high-fat diet, but only after insulin resistance has been established firmly after months of 
high-fat feeding [169]. This loss of mitochondrial function has been attributed to the oxidative 
stress encountered in the insulin-resistant state [169]. Together with the possible reversibility 
of fat-induced insulin resistance [211], these observations underscore the importance of a 
precise definition of insulin resistance development when judging mitochondrial engagement 
with disease progression. Moreover, the mitochondrial causality debate is clouded a little by 
the at times vague definition of mitochondrial dysfunction, and by the difficulty of measuring 
such function reliably. Also relevant for the debate is the notion that the many functions of 
mitochondria are dictated by their dynamic morphology. Indeed, the role of mitochondrial 
dynamics in nutrient metabolism and the metabolic syndrome is becoming increasingly clear 
[212]. With respect to mitochondrial models of insulin resistance (section 4), 2 key functions, 
oxidative phosphorylation and ROS production, warrant explicit discussion. 
5.2.1 Oxidative phosphorylation 
Cellular bioenergetic changes during development of muscle insulin resistance may be 
inferred from altered transcriptomic, proteomic and metabolomic signatures [154,155,213-
215], and also from changes in mitochondrial density and biogenesis [216,217]. Although 
invaluable, such circumstantial evidence requires functional bioenergetic measurements to 
confirm the topological effects are indeed reflected by changes in activity. However, it is very 
challenging to measure real-time mitochondrial ATP synthesis in a reliable way, particularly 
in physiologically relevant models. For instance, the mitochondrial ATP synthesis capacity of 
resting human skeletal muscle has been inferred from unidirectional flux between inorganic 
phosphate (Pi) and ATP as measured in vivo by 
31P MRS magnetization transfer [26,148-
151]. The interpretation of such transfer data is difficult for two reasons: (i) in resting muscle, 
the flux between Pi and ATP is dominated by a glycolytically mediated exchange, and (ii) 
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resting ATP synthesis does not reflect mitochondrial respiratory capacity calculated from ex 
vivo or in vivo oxygen uptake measurements [218-221]. Based on thorough meta-analysis of 
published literature, Kemp and Brindle conclude that 31P MRS magnetization transfer studies 
do not tell anything about mitochondrial function [221]. This conclusion clearly weakens the 
case in favour of causal involvement of mitochondrial dysfunction in development of muscle 
insulin resistance, as this case is largely built on magnetization transfer studies. 31P MRS 
measurements of PCr recovery following exercise, on the other hand, do indeed reflect the 
mitochondrial capacity of making ATP [221], but have so far yielded conflicting evidence 
[222-227]. As argued in section 5.1, PCr recovery deficiencies in human skeletal muscle with 
inborn insulin signalling defects suggest mitochondrial dysfunction is a result, not cause, of 
insulin resistance [207,208]. 
5.2.2 Mitochondrial ROS 
The case for causal involvement of ROS in obesity-related skeletal muscle insulin resistance 
has been made convincingly [53,54]. Although such involvement implicates mitochondria as 
likely causal players in disease pathology, it remains unclear if harmful ROS indeed originate 
in mitochondria and, if so, which of the 11 ROS-producing sites that have been described to 
date [185] are responsible for their production. In this respect, it is worth note that PDC has 
recently been discovered as a mitochondrial site that generates H2O2 under conditions of 
nutrient excess [228]. Under physiological conditions, PDC forms a redox circuit with the 
nicotinamide nucleotide transhydrogenase to keep ROS levels low during pyruvate oxidation 
[193]. Interestingly, metabolic modelling links PDC to insulin resistance phenotypes [229] 
and the enzyme is part of the ‗metabolic inflexibility‘ model of nutrient-induced muscle insulin 
resistance [108] (cf. section 4.3). 
Generally, it is unclear for many of the ROS-generating sites whether they produce 
superoxide, H2O2, or both [185]. It is important to establish the exact source and nature of 
the ROS that are produced under physiological and pathological  conditions in skeletal 
muscle, as it will help distinguish between mechanisms that could explain beneficial and 
deleterious ROS effects on insulin signalling [54]. Current consensus [53,54] has it that the 
oxidative stress causing insulin resistance is non-radical [111], i.e., that negative effects on 
insulin signalling are mediated through H2O2-modulation of ‗cysteine switches‘ on relevant 
tyrosine kinases and phosphatases (cf. section 3.2). However, radical ROS damage [111] is 
a likely contributor to pathology given the accumulation of lipid peroxidation products in 
human skeletal muscle of insulin resistant obese people [119]. Lipid peroxidation is initiated 
by the highly reactive hydroxyl radical (HO•) that arises through reaction between H2O2 and 
free iron. This Fenton chemistry may be driven by superoxide that is responsible for the 
required reduction of free iron, a species that indeed accumulates in muscle of obese 
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humans [230]. Mitochondria are not the only source of ROS in skeletal muscle cells, as 
superoxide can also be produced in the plasma membrane by NADPH oxidases [231], in 
peroxisomes during  and  oxidation of NEFAs [232,233] and in the ER as result of 
enzyme-catalysed sulphydryl oxidation during protein folding [234,235]. Indeed, debate on 
the relative importance of the various ROS sources for the regulation of insulin signalling is 
ongoing [53,54,236]. The need for establishing the exact sources of skeletal muscle ROS is 
underscored by the growing appreciation that ROS origin dictates whether their physiological 
effects are beneficial or detrimental [237,238]. Intuitively, the importance of location is 
obvious as ROS are short-lived and highly reactive by definition. In this respect, it is worth 
mention that mitochondria are mobile organelles [239,240] that, in principle, could find their 
way to any place within the cell. Precise understanding of ROS nature and origin is evidently 
very important if translational potential of possible modulation of redox biology in treatment 
or prevention of muscle insulin resistance is to be realized. Such understanding is currently 
hampered by the difficulty of measuring ‗native‘ rates [241] of ROS production in 
physiologically meaningful systems. Recently developed superoxide suppressors [242,243] 
and targeted ROS probes [244] will be invaluable tools in this respect. 
6. ENERGY DEMAND 
The mitochondrial causality debate is not only ongoing because of technical issues (section 
5.2), but also because it remains insufficiently appreciated that myocellular bioenergetics are 
fully controlled by energy demand. This control structure is evident from the observation that 
acute inhibition of ATP turnover in skeletal muscle cells causes an immediate decrease of 
mitochondrial ATP synthesis [34]. Moreover, muscle adapts to more persistent energy stress 
by increasing its mitochondrial capacity [245,246], a response that is regulated by the AMP-
activated protein kinase (AMPK). The demand-driven flux of ATP is reminiscent of a market 
economy where supply of goods is dictated by consumer (not producer) needs. Importantly, 
by controlling ATP flux this way, skeletal muscle cells can satisfy wide-ranging energetic 
demands whilst keeping their phosphorylation potential – which links ATP supply with ATP 
demand – under tight homeostatic control and far removed from its thermodynamic 
equilibrium [247]. Indeed, the oxidative phosphorylation rate in skeletal muscle may fluctuate 
several orders of magnitude without discernable effect on the ATP/ADP ratio. The notion 
that skeletal muscle ATP synthesis is demand-driven has major ramifications for interpreting 
the association between mitochondrial dysfunction and nutrient-induced loss of insulin 
sensitivity. Muoio and Neufer indeed argue persuasively that many paradoxical observations 
in the literature are readily reconciled when the discrepant energetic needs of the studied 
experimental models are considered [45]. As discussed by Kemp and Brindle (cf. section 
5.2.1), quantification of ‗mitochondrial‘ ATP synthesis by MRS-based measurement of 
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unidirectional flux between Pi and ATP in resting muscle has no straightforward relation with 
mitochondrial oxidative capacity [221], for the simple reason that such resting flux is set by 
sub-maximal energy demand. Similarly, determination of skeletal muscle glycolytic capacity 
is easily confounded by restricted ATP demand [248]. In this section, the importance of 
energy demand for maintaining skeletal muscle insulin sensitivity is highlighted by pointing 
out how AMPK relates to the current clinical management of the metabolic syndrome, and 
by exploring the possibility that mitochondrial dysfunction may arise during development of 
muscle insulin resistance as a consequence of compromised ATP turnover. 
6.1 AMP-activated protein kinase 
AMPK is a serine/threonine protein kinase that has been highly conserved through evolution 
and is generally considered the ‗master regulator‘ of energy metabolism in a wide range of 
tissues [249,250]. AMPK is activated under conditions of energetic stress (e.g. exercise) 
where high ATP demand increases the level of AMP. Broadly speaking, activated AMPK 
stimulates energy-liberating mechanisms and dampens ATP-consuming processes thus 
restoring cellular energy balance [251]. In skeletal muscle, AMPK for example promotes 
NEFA oxidation [252,253], glucose uptake [254,255] and protein degradation [256], whereas 
it attenuates lipogenesis [257,258], glycogenesis [259,260] and protein synthesis [261]. 
Simultaneous stimulation of NEFA oxidation and glucose uptake is at odds with the Randle 
cycle (cf. section 4.3) and AMPK activation indeed overrules metabolic fuel selection 
mechanisms [200]. Notably, glucose uptake is virtually insulin-independent during exercise 
[262]. Moreover, chronic AMPK activation triggers mitochondrial biogenesis [245] and 
increases mitochondrial protein content [246]. Most evidence for the AMPK regulation of 
these physiological processes has been gathered from rodent work, but fuel homeostasis via 
AMPK regulation may well benefit human skeletal muscle insulin sensitivity [250]. Indeed, 
AMPK is seen as target for clinical management of muscle insulin resistance [263], although 
pharmacological AMPK stimulation without increasing energy expenditure fails to lower 
murine adiposity [264]. Importantly, however, it transpires that the insulin-sensitizing drugs 
metformin [265,266] and the thiazolidinediones [267,268] (TZDs), exert their beneficial 
metabolic effects at least in part by increasing AMPK activity. Mechanisms by which these 
antidiabetic drugs lead to AMPK activation have not been established conclusively [267]. 
Metformin inhibits mitochondrial respiratory complex I [269], which is expected to 
compromise oxidative phosphorylation and thus to lower cellular ATP levels [266,270]. 
Paradoxically, activated AMPK will boost NEFA oxidation, a process that will not operate 
without involvement of complex I, contrary to what has been suggested elsewhere [250,271]. 
It is interesting to note in this context that TZDs inhibit pyruvate uptake into mitochondria 
[272], an effect that could perhaps stimulate  oxidation, although it would prevent complete 
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catabolism of the AMPK-increased glucose. Reciprocally, it has been shown that increased 
glucose utilization following chronic inhibition of NEFA oxidation [206,273] and consequent 
improvement insulin sensitivity [274] are associated with AMPK activation and increased 
exercise capacity, respectively. 
6.2 ATP turnover 
Opponents of the oxidative capacity model of skeletal muscle insulin resistance argue that 
resting skeletal muscle should have sufficient reserve respiratory capacity to deal with the 
excessive nutrient supply that prevails in obesity [202]. Such reserve will be inconsequential, 
however, if the demand for it is lacking. In other words, the effective oxidative capacity is 
largely determined by energy expenditure, and it is therefore conceivable that mitochondrial 
respiratory ‗dysfunction‘ associated with elevated NEFA levels reflects decreased ATP 
turnover (Fig. 6). Indeed, insulin-numbing exposure of cultured rat and primary human 
myoblasts to palmitate coincides with a significantly decreased rate of de novo protein 
synthesis [34]. This anabolic process is a major ATP consumer in most cells and its 
inhibition by palmitate in skeletal muscle cells provokes mitochondria to reserve less ATP for 
making new protein. In response to palmitate, mitochondria also lower ATP supply that is 
used in human myoblasts for making DNA and RNA, and for maintaining appropriate sodium 
and potassium gradients across the plasma membrane. More generally, various saturated 
and unsaturated NEFAs dampen the overall absolute rate of mitochondrial ATP supply, 
which may well be a consequence of lower ATP demand [34]. This finding demonstrates that 
depressed mitochondrial respiration does not necessarily imply intrinsic defects, but could 
merely be an adaptation to altered energy demand. Lipotoxicity may in principle compromise 
many endergonic cellular functions [275] and possible harmful effects of palmitate on ER-
mediated protein folding [276], a process that consumes much ATP, are worth mention in 
this respect. On the other hand, lipotoxicity may well trigger cellular stress responses that 
increase ATP turnover, and mitochondrial respiratory adaptation will likely reflect the net 
outcome of diverse NEFA effects on ATP-consuming processes. Indeed, indirect effects of 
nutrient excess on the effective oxidative capacity mediated via altered energy expenditure 
could also provide a mechanism for the apparent mitochondrial dysfunction that follows from 
inborn insulin signalling deficiency [207]. Congenital defects in the insulin receptor are 
expected to dampen the anabolic response of skeletal muscle to insulin (Figs 2 and 6). The 
consequent attenuated energy demand may well be responsible for the apparent decrease 
of mitochondrial ATP synthesis capacity. From a clinical perspective, it is conceivable that 
the variable propensity of obese people to develop metabolic disease – almost three-
quarters of people with a body mass index of more than 40 kg/m2 do not suffer from diabetes 
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[277] – partly relates to differences in the sensitivity of muscle energy expenditure to nutrient 
overload amongst individuals. 
 
Figure 6 – Mitochondrial dysfunction in obese skeletal muscle. Oversupply of non-esterified fatty acids 
(NEFAs) may impair the oxidative phosphorylation machinery directly. In addition, mitochondrial activity may 
decrease in response to nutrient-induced attenuation of energy expenditure. 
 
7. CONCLUSION 
Mitochondrial dysfunction is associated with skeletal muscle insulin resistance and studies 
on human subjects with congenital insulin signalling defects demonstrate unequivocally that 
mitochondrial defects can result from ab initio insulin resistance. Evidence for a possible 
causal role of mitochondrial dysfunction in development of insulin resistance is less direct. 
Proposed mechanisms by which imbalanced bioenergetics can produce deleterious lipids 
and ROS are intuitively attractive, but support for the conceptually similar models remains 
circumstantial. The reported dampening effects of DAG, ceramide and hydrogen peroxide on 
insulin signalling are compelling, but links between mitochondrial oxidative capacity, lipid 
intermediates and insulin resistance are far from universal, and it is also not conclusively 
clear if harmful ROS indeed originate in mitochondria. Improved measurement of (i) lipid 
composition and subcellular location, (ii) real-time oxidative phosphorylation activity, (iii) 
native rates by which different ROS sources generate superoxide, hydrogen peroxide and, 
indirectly, hydroxyl radicals, and indeed of (iv) insulin sensitivity itself, which may deteriorate 
without changes in canonical signalling pathways, should enlighten the causality debate. As 
it stands, it seems plausible that changes in mitochondrial function that occur relatively late 
during development of muscle insulin resistance will exacerbate pathology. It is equally 
conceivable that mitochondrial insufficiencies or deficiencies coincide with harmful effects of 
nutrients and cytokines on other cellular targets, and that the onset of insulin resistance is 
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triggered by multifarious independent defects. A challenge of this causal scenario would be 
to unravel the possible interplay between the initial effects, and to establish their relative 
importance. If mitochondria are indeed not involved during early disease pathology, then it 
remains to be demonstrated how insulin resistance causes the reported functional 
mitochondrial defects. Addressing this issue, mitochondrial function will be best evaluated in 
context of cellular bioenergetic control, as loss of insulin sensitivity likely remodels ATP-
consuming processes, and mitochondria will indeed adapt to such remodeling of energy 
demand. It may thus be fairly obvious to conclude that mitochondrial involvement in obesity-
related insulin resistance of skeletal muscle is ‗a case of imbalanced bioenergetics‘, but it is 
currently far less trivial to judge which side of the balance is tipped to upset the peace. 
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Highlights 
• Mitochondrial models of obesity-related skeletal muscle insulin resistance are 
reviewed. 
• Nutrient-induced insulin resistance is characterised by imbalanced cellular 
bioenergetics. 
• Mitochondrial ‘dysfunction’ may be an adaptive response to decreased energy 
demand. 
